Caladrius Biosciences, Inc. announced that four additional clinical sites, including Joslin Diabetes Center, an affiliate of Harvard Medical School, under the direction of investigator Jason L. Gaglia, MD, have opened to enroll subjects for the Company's Phase 2 clinical trial of CLBS03 in type 1 diabetes, The Sanford Project: T-Rex Study. The other clinical sites include Children's Mercy Hospital (under Mark A. Clements, MD), the University of Miami Diabetes Research Institute (under David Baidal, MD) and Vanderbilt University Hospital (under Daniel J. Moore, PhD, MD).

These four clinical sites join existing clinical sites for the T-Rex Study at Sanford Research (Sioux Falls, South Dakota under Kurt Griffin, MD, PhD and Fargo, North Dakota under Luis Casas, MD), Indiana University under Linda DiMeglio, MD, MPH, UCSF Benoiff Children's Hospital San Francisco under Stephen Gitelman, MD, the Barbara Davis Center for Diabetes in Aurora, Colorado under Peter Gottlieb, MD, the Harold Schnitzer Diabetes Health Center at Oregon Health & Science University under Ines Guttman-Bauman, MD and University of Florida Diabetes Institute under Michael Haller, MD.